Notice of Intent to issue a Sole Source Award for a GentleMACS Octo Dissociator with Heaters 75D30126Q78901
Summary
AI-generated · Mar 24, 2026Procurement of 1 GentleMACS Octo Dissociator with heating units, plus an instrument service plan, from Miltenyi Biotec Inc. under a sole-source award. The device is the only commercially available system that can simultaneously process eight biological samples in a fully closed, sterile setup with integrated heating and validated SOPs per the QMML. Its patented, proprietary dissociation architecture enables reproducible, high-viability single-cell and nuclei preparations across tissue types, and it includes OEM-developed, tissue-specific programs that require no additional programming. It supports required consumables (C Tubes and M Tubes) to maintain sterility and traceability and shows proven compatibility with downstream Luminex and single-cell sequencing workflows under current quality and regulatory standards.
The government intends to negotiate with only one source under FAR 12.102(a). This notice is not a request for competitive quotations; however, responses received within 15 days of issuance will be considered. Any response should be directed to the contract specialist.
The Centers for Disease Control and Prevention s National Center for Immunization and Respiratory Diseases (NCIRD)/Influenza Division (ID) intends to award a sole source firm fixed price purchase order to Miltenyi Biotec Inc, UEI # ZLDPMHA3M333, 2303 Lindbergh St, Auburn, Ca 95602, to provide 1 GentleMACS Octo Dissocciator with heating units with an instrument service plan. Miltenyi Biotec Inc GentleMACS Octo Dissocciator with heating units is the only commercially available instrument capable of simultaneously processing eight biological samples in a fully closed, sterile system with integrated heating and validated programmable protocols that are already incorporated into the validated Standard Operating Procedures (SOPs) per the Quality Manual for Microbiological Laboratories (QMML). The systems proprietary mechanical dissociation architecture, protected by active patents, allows for reproducible, high-viability single-cell and nuclei preparations across multiple tissue types without operator-dependent variability. It is also the only system with OEM-developed, tissue-specific programs that can be run without additional programming or third-party modification, and it supports the required consumable formats (C Tubes and M Tubes) that maintain sterility and traceability. No other system combines these capabilities with proven compatibility for downstream Luminex and single-cell sequencing workflows under current quality and regulatory requirements. This contract action is for a commercial supply for which the Government intends to solicit and negotiate with only one source under the authority of FAR 12.102(a). This notice of intent is not a request for competitive quotations; however, all quotations/responses received within 15 days of the issuance of this notice will be considered by the government. A determination by the government not to complete this proposed purchase order based upon responses to this notice is solely within the discretion of the government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to the contract specialist at email zvm0@cdc.gov by 04/07/2026.
From Presolicitation posted on Mar 23, 2026Notice history
1-
Presolicitation LATEST Posted Mar 23, 2026
Details
Award Information
Not yet awarded
Contacts
Phone
Phone
Agency
Place of Performance
USA